Pediatric Cancer Trials: US FDA Panel To Weigh Use Of Real-World Data, Patient-Reported Outcomes

 
• By Sue Sutter

Advisory committee will discuss ways to encourage inclusion of the Pediatric PRO-CTCAE tool in cancer trials on 11 May, followed the next day by a discussion on real-world data sources that could inform the efficacy and long-term safety of pediatric cancer treatments.

Girl with diary
An FDA panel will discuss the utility of patient self-reporting in pediatric cancer trials. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers